¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"theory of antibody formation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibody diversity
    Ç×ü´Ù¾ç¼º
  • antibody excess
    Ç×ü°úÀ×
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody removal
    Ç×üÁ¦°Å
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody valence
    Ç×ü°áÇÕ°¡
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î¼º
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • general system theory
    ÀϹÝü°è·Ð
  • germ line theory
    Ç×ü³»¸²¹°·Á¹Þ±â¼³
  • hemodyamic theory
    Ç÷¾×µ¿·Â¼³
  • instinct theory
    º»´ÉÀÌ·Ð
  • instructive theory
    (¢¡template theory) Ç×ü»ý»êÁö½Ã¼³, Ç×ü»ý»êÃø¼â¼³
  • internuncial pool theory
    ½Å°æ¼¼Æ÷»çÀÌÀúÀå·Ð
  • interpersonal theory
    ´ëÀÎÀÌ·Ð
  • libido theory
    ¸®ºñµµ·Ð
  • menophylectic theory
    ÀÏ¿ø¼³
  • object relation theory
    ´ë»ó°ü°è·Ð
  • organismic theory
    À¯±âüÀÌ·Ð
  • personality theory
    ÀΰÝÀÌ·Ð
  • protovirus theory
    ÇÁ·ÎÅä¹ÙÀÌ·¯½ºÁ¾¾çÀ¯¹ß·Ð
  • psychoanalytic theory
    Á¤½ÅºÐ¼®ÀÌ·Ð
  • quantum theory
    ¾çÀÚ·Ð
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • polychromatic theory
    ´Ù»ö¼³
  • psychoanalytic theory
    Á¤½ÅºÐ¼®ÇÐÀÌ·Ð(¡­ùÊìµÖå).
  • quantum theory
    ¾çÀÚ·Ð.
  • radiation,target theory of
    ¡­ÀÇ Ç¥ÀûÀÌ·Ð(¡­øöîÜìµÖå)
  • DF3 antibody
    DF3 Ç×ü
  • DL antobody => Donath-Landsteiner antibody
    DL Ç×ü
  • Donath-Landsteiner antibody
    µµ³ª¾²¶õÆ®½ºÅ¸ÀÌ³Ê Ç×ü
  • FTA (fluorescent treponemal antibody)
    ¸Åµ¶Çü±¤Ç×ü °Ë»ç¹ý
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
  • Gp 120/160 antibody
    Gp 120/160 Ç×ü
  • Gp 24 antibody
    Gp 24 Ç×ü
  • I antibody
    I Ç×ü
  • Jk antigen/antibody
    JkÇ׿ø/Ç×ü
  • Jo-1 antibody
    Jo-1 Ç×ü
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • free radical formation,lipid peroxidation
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, ÁöÁú °ú»êÈ­(ò·òõ Φ߫ûù)
  • free radical formation,oxygen derived
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, »ê¼Ò ±â¿ø¼º(ß«áÈ ÑÃê¹àõ)
  • free radical formation,oxygen toxicity
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, »ê¼Òµ¶¼º(ß«áÈÔ¸àõ)
  • free radical formation,propagation
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, ÀüÆÄ
  • free radical formation,redox reactions
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, »êȭȯ¿ø¹ÝÀÀ(ß«ûùü½êªÚãëë)
  • free radical formation,superoxide dismutase
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, °ú»êÈ­ dismutase
  • immunoglobulin M formation
    ¸é¿ª±Û·ÎºÒ¸° M Çü¼º
  • impulse formation
    ÈïºÐÆÄ»ý¼º.
  • janiceps formation
    ÀϵÎÀ̾ÈüÇü¼º(¡­û¡à÷).
  • lactic acid formation
    À¯»êÇü¼º
  • language formation cortex
    ¾ð¾îÇü¼ºÇÇÁú.
  • lateral reticular formation
    ¿ÜÃø¸Á»óü(¡­ØÑßÒô÷).
  • lymph formation
    ¸²ÇÁÇü¼º.
  • macrophage formation
    ´ë½Ä¼¼Æ÷ Çü¼º
  • myelin formation
    ¼öÃÊÇü¼º(âÐôúû¡à÷).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cold antibody
    ³ÃÇ×ü(Ò²ù÷ô÷)
  • complement-fixing antibody
    º¸Ã¼°íÁ¤ Ç×ü(ÜÍô÷ͳïÒù÷ô÷)
  • complete antibody
    ¿ÏÀüÇ×ü(èÇîïù÷ô÷)
  • coprecipitating antibody
    °øÄ§Àü(ÍìöØîþ) Ç×ü(ù÷ô÷)
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀ Ç×ü(Îßó©Úãëëù÷ô÷)
  • cytophilic antibody
    ¼¼Æ÷ģȭÇ×ü(á¬øàöÑûúù÷ô÷)
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼º Ç×ü(á¬øàÔ¸àõù÷ô÷)
  • cytotropic antibody
    ¼¼Æ÷ģȭ¼º Ç×ü(á¬øàöÑûúàõù÷ô÷)
  • direct fluorescent antibody technique
    Á÷Á¢ Çü±¤ Ç×ü¼ú(òÁïÈû«ÎÃù÷ô÷âú)
  • ferritin-labeled antibody
    Æä¸®Æ¾Ç¥Áö(øöò½) Ç×ü(ù÷ô÷)
  • fluorescent antibody
    Çü±¤ Ç×ü(û«ÎÃù÷ô÷)
  • fluorescent antibody technique
    Çü±¤ Ç×ü¼ú(û«ÎÃù÷ô÷âú)
  • fraction-antibody binding
    ºÎºÐÇ×ü °áÇÕ(Ý»ÝÂù÷ô÷Ì¿ùê)
  • hemolytic antibody
    ¿ëÇ÷ Ç×ü(éÁúìù÷ô÷)
  • heterocytotropic antibody
    ÀÌÁ¾Ä£È­¼º Ç×ü(ì¶ðúöÑûúàõù÷ô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
PPRF Pontine Paramedian Reticular Formation
BFR biologic false reaction; blood flow rate; bone formation rate; buffered Ringer [solution]
DMRF dorsal medullary reticular formation
ECF effective capillary flow; eosinophilic chemotactic factor; erythroid colony formation; extended care...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
IIF Intracellular Ice Formation
MRF Mesencephalic Reticular Formation
P.R.F. Pontine Reticular Formation
HPC hippocampal formation
LRF lateral reticular formation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • aging,free radical theory
    À¯¸®±â¼³
  • alternation theory
    ±³¹ø¼³
  • apposition theory
    ºÎÂø¼³
  • biophysical theory
    »ý¹°¸®Çм³
  • Burnet's clonal selection theory
    ?
  • chemo-parasitic theory
    È­ÇÐ ¼¼±Õ¼³
    ¿ì½ÄÀÇ ¿øÀο¡ °üÇÏ¿© Miller°¡ ¼¼¿î Çм³. ¿ì½ÄÀÇ ¹ß»ýÀº Ä¡¾ÆÀÇ ÁÖü¸¦ ÀÌ·é ¼®È¸¿°ÀÇ Å»È¸À̰í, ±× ¿øÀÎÀÌ µÇ´Â »êÀº À½½Ä¹° Áß¿¡ Æ÷ÇԵǾî Àִ ź¼öÈ­¹°À» ±¸°­³»ÀÇ ¼¼±ÕÀÌ ¹ßÈ¿ÇϹǷΠÀÎÇØ¼­ »ý±â´Â À¯±â»êÀ̶ó´Â °¡¼³À» ¼¼¿ü´Ù. Miller´Â ¿ì½Ä Á¶Á÷À» È­ÇÐÀûÀ¸·Î ºÐ¼®ÇÏ°í ±×°Í¿¡ Æ÷ÇԵǾî ÀÖ´Â Ä®½·°ú À¯±âÁúÀÇ ¾çÀÌ ÀÌ»óÇÏ°Ô °¨¼ÒµÇ¾î ÀÖ´Â °ÍÀ» ¾Ë¾Ò´Ù. Áï ¿ì½Ä Ç¥ÃþºÎÀÇ ¿¬È­ »ó¾ÆÁúÀº Á¤»óÀÇ Ä¡Áú¿¡ ºñÇÏ¿© 92.5%ÀÇ Ä®½·°ú 39.4%ÀÇ À¯±âÁúÀÌ ¼Õ½ÇµÇ¾î ÀÖ°í ¿ì½Ä ½ÉºÎ¿¡¼­´Â 22.0%ÀÇ Ä®½· »ó½ÇÀ» ³ªÅ¸³Â´Ù. ±×·¯¹Ç·Î ±×´Â ½ÇÇèÀ» ÅëÇÏ¿© Ä¡¾Æ¿¡ À¯±â»ê°ú »§°¡·ç¸¦ ¼¯Àº °ÍÀ» ¾È¿¡ ºÙ¿© ³õÀº °á°ú, »ýÈ­ÇÐÀûÀ¸·Î ¿ì½Ä°ú ºñ½ÁÇÑ »óŰ¡ ÀϾ´Â °ÍÀ» ±ú´Ý°í, ¿ì½ÄÀÇ °æ¿ì´Â »êÀÌ Å« ÀÛ¿ëÀ» Çϸç, ±× À¯±â»êÀº »ó¾Æ¼¼°ü³»³ª Ä¡¾ÆÀÇ Ç¥¸é¿¡¼­ º¼ ¼ö ÀÖ´Â ´ÙÁ¾ ´Ù¾çÀÇ ¼¼±Õ¿¡ ÀÇÇØ¼­ À½½Ä¹° Àܻ翡 Æ÷ÇÔµÈ Åº¼öÈ­¹°ÀÇ ¹ßÈ¿¿¡ ÀÇÇÑ °ÍÀ̶ó°í »ý°¢ÇÏ¿´À¸³ª ±×´Â ±× ÁÖ¿ªÀ» ¸ÃÀº ¼¼±ÕÀÌ ¹«¾ùÀΰ¡´Â ¾ð¸íÇÏÁö ¾Ê¾Ò´Ù. ÀÌ È­ÇÐ ¼¼±Õ¼³Àº Èļ¼±îÁö °­ÇÑ ¿µÇâÀ» ¹ÌÄ¡°í ¿ì½ÄÀÇ ¼¼±ÕÇÐÀû ¿¬±¸ÀÇ ÁÖ·ù¸¦ ÀÌ·ç¾î ¿Ô´Ù.
  • clonal selection theory
    Ŭ·Ð ¼±Åü³
  • Combinational theory
    Á¶ÇÕ¼³
    Ç×ü ¹ßÇöÀÇ ´Ù¾ç¼ºÀ» ¼ø¿­ Á¶ÇÕ¿¡¼­ ±¸ÇÏ´Â Çм³.
  • contagium theory
    Àü¿°¼³, °¨¿°¼³
  • doublet theory
    ÀÌÁß±Ø ¼³
  • Ehrlich`s side chain theory
    ¿¡¸¦¸®È÷ÀÇ Ãø¼â¼³
    Ç×ü »ý»ê ±âÀü¿¡ ´ëÇÏ¿© Á¦¾ÈµÈ °¡¼³ÀÇ Çϳª. ¸ðµç ü ¼¼Æ÷ Ç¥¸é¿¡´Â Ãø¼â¶ó°í ÇÏ´Â ¼ö¿ëü°¡ ÀÖ°í, À̰Ϳ¡ ´ëÀÀÇÏ´Â Ç׿øÀÌ °áÇÕÇϸé Ȱ¼ºÈ­ µÇ°í, Ãø¼â°¡ °úÀ× »ý»êµÇ¾î Ç×ü·Î¼­ Ç÷·ù ¼Ó¿¡ ¹æÃâµÈ´Ù°í ÇÏ´Â »ý°¢. Ç×ü »ý»êÀÇ ¼±Åü³ÀÇ ÃÖÃÊÀÇ °ÍÀÌ´Ù.
  • epoigenetic theory
    Èļº¼³
  • error accumulation theory
    ¿ÀÂ÷ ´©Àû¼³
    ³ëÈ­ÀÇ ¿øÀÎÁõ.
  • evolution theory
    ÁøÈ­·Ð
  • fluid mosaic theory
    À¯µ¿ ¸ðÀÚÀÌÅ© ¼³
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
antibody induced lysis <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis.
See: complement lysis, natural killer cells.
(09 Feb 1998)
antibody producing cell <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell.
(18 Nov 1997)
antibody-producing cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise.
(12 Dec 1998)
antibody specificity The property of antibodies which enables them to react with some antigenic determinants and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
(12 Dec 1998)
antibody technology <molecular biology> Techniques for the synthesis of polyclonal and monoclonal antibodies for use in research, diagnostics and therapeutics.
(09 Feb 1998)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
anti-idiotype antibody <immunology> An antibody directed against the antigen specific part of the sequence of an antibody or T-cell receptor and thus recognise the binding sites of other antibodies.
In principle an anti-idiotype antibody should inhibit a specific immune response and they are important to the regulation of the immune system.
(13 Nov 1997)
anti-insulin antibody A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result.
(27 Sep 1997)
antinuclear antibody <immunology> Antinuclear antibody is an antibody that react against components of the cell nucleus such as DNA, RNA, histone or non-histone proteins.
These antibodies are present in a variety of immunologic or autoimmune diseases including systemic lupus erythematosus, systemic sclerosis, scleroderma, Sjogren's syndrome, rheumatoid arthritis, polymyositis, dermatomyositis and in persons taking hydralazine, procainamide or isoniazid.
A serologic measurement for antinuclear antibodies can aid in the diagnosis of unexplained arthritis, rashes or chest pains.
Acronym: ANA
(12 Jan 1998)
anti-P antibody <haematology, investigation> A serologic blood test used to detect the Donath-landsteiner antibody in serum.
This test is performed in cases of suspected paroxysmal cold haemoglobinuria. A normal result is indicated by an absence of antibodies. The antibody is directed toward the P-antigen complex which is located on the surface of red blood cells. In some way, cold temperatures trigger the antibody to bind to this site.
(13 Jan 1998)
antiparietal cell antibody <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells.
Less than 2% of the general population will be antibody positive although this can be higher in the elderly.
Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes.
(13 Jan 1998)
antiphospholipid antibody <immunology, syndrome> An uncommon disorder that is characterised by hypercoagulability due to the presence of antibodies against phospholipids.
These patients exhibit a tendency for recurrent and life-threatening thrombosis and embolic events (for example stroke). Individuals with antiphospholipid syndrome also have an increased tendency toward deep venous thrombosis, myocardial infarction and spontaneous abortions in females.
Antiphospholipid syndrome may be seen by itself or in association with other autoimmune illnesses (for example lupus) or with some infections.
Treatment includes long-term heparin and warfarin.
(13 Jan 1998)
antiphospholipid antibody syndrome <syndrome> An immune disorder characterised by the presence of abnormal antibodies in the blood associated with certain medical conditions including abnormal blood clotting, migraine headaches, premature miscarriage, and low blood platelet counts (thrombocytopenia).
(12 Dec 1998)
antithyroglobulin antibody <endocrinology, immunology> A serologic blood test which measures the antithyroglobulin antibodies in the blood. Thyroglobulin is a protein found in thyroid tissue. It is the source of thyroid hormones in the body.
The presence of antibodies to this protein can result in decreased thyroid gland function. A negative assay is considered normal.
Conditions where the assay may be positive include: lupus, rheumatoid arthritis, Hashimoto's thyroiditis, thyrotoxicosis, hypothyroidism, thyroid cancer, myxoedema, Sjogren's syndrome and autoimmune haemolytic anaemia.
(13 Jan 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • interpretive semantics(theory)
    (¾ð)ÇØ¼® Àǹ̷Ð
  • nebular hypothesis(theory)
    (õ)(žç°èÀÇ)¼º¿î¼³
  • quantum theory
    ¾çÀÚ·Ð
  • stress theory
    (ij³ª´ÙÀÇ H,Selye ±³¼ö ÁÖâÀÇ)½ºÆ®·¹½º Çм³
  • theory
    Çм³;¼³;ÀÌ·Ð;(Ź»óÀÇ)°ø·Ð
  • transformation theory
    º¯Çü¼³
  • trickledown theory
    Æ®¸®Å¬´Ù¿î ÀÌ·Ð(´ë±â¾÷¿¡ÀÇ ÀçÁ¤Àû ¿ì´ë´Â Áß¼Ò±â¾÷À̳ª ¼ÒºñÀÚ¿¡°Ô ÆÄ±ÞÈ¿°ú¸¦ Áشٴ ¼³)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á